What rationale, guidance and evidence is there for the use of phosphodiesterase-5 inhibitors as supportive therapy to rehabilitate erectile function after nerve sparing radical prostatectomy?

· UKMi

Erectile dysfunction is a common complication following prostatectomy. Phosphodiesterase 5 inhibitors (sildenafil, tadalafil, vardenafil or avanafil), used either daily or on demand following prostatectomy, have been shown to reverse or minimise this complication.  This Q&A explores the rational and evidence for this.